Skip to content
Subscriber Only

Amarin Sues FDA Over Exclusivity for Fish Oil Pill

Amarin Corp., the maker of the fish oil pill Vascepa, asked a federal judge to order the U.S. Food and Drug Administration to give it exclusive marketing rights to the product for five years.

The FDA agreed with Amarin that Vascepa and a competing drug to combat trigylcerides in the bloodstream, Lovaza, have different active ingredients, yet the agency “refused to recognize five-year statutory exclusivity for Vascepa,'' the Dublin-based company said in a complaint filed today in Washington.